Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01194440 · ClinicalTrials.gov registry record · Phase 2
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT01194440 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 63 participants.
The verdict
NCT01194440, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
RATIONALE: Zoledronic acid may prevent bone loss and help prevent or lessen musculoskeletal symptoms in women receiving hormone therapy for breast cancer. PURPOSE: This phase II trial is studying how well zoledronic acid works in preventing musculoskeletal symptoms in post-menopausal women with stage I, stage II, or stage III breast cancer receiving letrozole.
Interventions
- DRUG letrozole
- DRUG zoledronic acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2011-02 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01194440
The ClinicalTrials.gov registry entry for NCT01194440 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which letrozole is the first listed.
NCT01194440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01194440 about?
NCT01194440 is a clinical study titled "Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms". RATIONALE: Zoledronic acid may prevent bone loss and help prevent or lessen musculoskeletal symptoms in women receiving hormone therapy for breast cancer. PURPOSE: This phase II trial is studying how well zoledronic acid works in preventing musculoskeletal symptoms in post-menopausal women with sta...
What is the current status of trial NCT01194440?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2011-02. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01194440?
The interventions under investigation include: letrozole (DRUG), zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT01194440?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.